Adam Czakański is carving out a unique space in the world of hedge funds. As a former analyst at Millennium Management—one of the world's largest multi-strategy hedge funds with over $70 billion in ...
During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS), revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...
Excipient market growth driven by innovation, compliance needs, and digital procurement, with emphasis on supply resilience, ...
The pharmaceutical sector is entering 2026 at a critical juncture. While recent initial public offering (IPO) performance has been stellar, with pharma firms claiming five of the top 10 IPO returns ...
Making changes in the pharma industry in operations is a slightly more expensive process because of larger compliances and regulatory pieces involved. Last-mile-issues impact any industry that relies ...
July 24 (Reuters) - West Pharmaceutical (WST.N), opens new tab raised its annual profit forecast and trimmed its estimates for tariff impact on Thursday, sending the medical equipment maker's shares ...
Adopting robotics in pharma boosts resilience, precision, and compliance. Demand grows globally with diverse drug portfolios ...
According to MarketsandMarkets™, the Wearables in Pharma & Biotech Market is projected to grow from about USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%.
The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ahead after declining earnings in recent years. According to ZS consultant ...
Ratings for NewAmsterdam Pharma Co (NASDAQ:NAMS) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results